Targets › NPM1
4 programs from 4 companies in 18 trials: 9 Phase 2, 5 Phase 1, 2 Phase 3, 2 Phase 4; Oncology; next expected readout Jan 2027.
Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. (UniProt, P06748)
Open in Phaseline: the race on NPM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Ceritinib (LDK378) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | ALK, EML4, NPM1 | Phase 4 | ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive … | Apr 2027 |
| Pfizer | crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| IDEAYA Biosciences | Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| Miltenyi Biomedicine | MB-dNPM1-TCR.1 T cell receptor (TCR) therapy targeting dNPM1 peptide epitopes restricted to HLA A*02:01 | NPM1 | Phase 1 | Leukemia, Myeloid, Acute | Jun 2028 |
Advanced Lymphoma (4) Non-small Cell Lung Cancer (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Lung Cancer Stage III (1) Metastatic Colorectal Cancer (1) Advanced Malignant Solid Neoplasm (1) ALK Positive Malignancies (1) ALK-positive NSCLC (1) Neuroblastoma (1) ALK Positive (1)
small molecule (2), mixed (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.